SG11202012682PA - Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor - Google Patents

Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor

Info

Publication number
SG11202012682PA
SG11202012682PA SG11202012682PA SG11202012682PA SG11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA SG 11202012682P A SG11202012682P A SG 11202012682PA
Authority
SG
Singapore
Prior art keywords
benefit
treatment
methods
telomerase inhibitor
identifying patients
Prior art date
Application number
SG11202012682PA
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Fei Huang
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of SG11202012682PA publication Critical patent/SG11202012682PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Dermatology (AREA)
  • Signal Processing (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Bioinformatics & Computational Biology (AREA)
SG11202012682PA 2018-07-31 2019-07-29 Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor SG11202012682PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712841P 2018-07-31 2018-07-31
US201862772849P 2018-11-29 2018-11-29
PCT/US2019/043941 WO2020028261A1 (en) 2018-07-31 2019-07-29 Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor

Publications (1)

Publication Number Publication Date
SG11202012682PA true SG11202012682PA (en) 2021-02-25

Family

ID=69230556

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012682PA SG11202012682PA (en) 2018-07-31 2019-07-29 Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor

Country Status (15)

Country Link
US (1) US20200063214A1 (he)
EP (1) EP3829651A4 (he)
JP (2) JP7401518B2 (he)
KR (1) KR20210038895A (he)
CN (1) CN112770783A (he)
AU (1) AU2019315406A1 (he)
BR (1) BR112021001204A2 (he)
CA (1) CA3104537A1 (he)
CL (4) CL2021000251A1 (he)
IL (1) IL279623A (he)
MA (1) MA53348A (he)
MX (1) MX2021001255A (he)
SG (1) SG11202012682PA (he)
TW (1) TW202021626A (he)
WO (1) WO2020028261A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065828B1 (en) 2013-11-06 2019-01-09 Mayo Foundation for Medical Education and Research Methods and materials for treating hematological malignancies
WO2024147949A1 (en) * 2023-01-03 2024-07-11 Geron Corporation Methods of treating myelodysplastic syndrome and monitoring the treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200327B2 (en) * 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
SG11201504209YA (en) * 2012-11-30 2015-06-29 Geron Corp Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
DK3456333T3 (da) * 2012-12-07 2020-05-18 Geron Corp Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom
EP3065828B1 (en) 2013-11-06 2019-01-09 Mayo Foundation for Medical Education and Research Methods and materials for treating hematological malignancies
CN108138234A (zh) 2015-04-15 2018-06-08 普罗麦迪奥股份有限公司 治疗骨髓增生性障碍的方法

Also Published As

Publication number Publication date
US20200063214A1 (en) 2020-02-27
MX2021001255A (es) 2021-04-12
CA3104537A1 (en) 2020-02-06
JP2021531793A (ja) 2021-11-25
CL2022000262A1 (es) 2022-10-21
CL2021000251A1 (es) 2021-08-20
MA53348A (fr) 2022-05-04
IL279623A (he) 2021-03-01
BR112021001204A2 (pt) 2021-04-27
KR20210038895A (ko) 2021-04-08
CN112770783A (zh) 2021-05-07
TW202021626A (zh) 2020-06-16
EP3829651A4 (en) 2022-05-04
AU2019315406A1 (en) 2021-01-21
EP3829651A1 (en) 2021-06-09
CL2023003123A1 (es) 2024-04-19
WO2020028261A1 (en) 2020-02-06
JP7401518B2 (ja) 2023-12-19
CL2023003126A1 (es) 2024-04-19
JP2023164560A (ja) 2023-11-10

Similar Documents

Publication Publication Date Title
HUE060671T2 (hu) Eljárás fibrotikus betegségek kezelésére
ZA201906817B (en) Methods of treatment using a jak inhibitor compound
IL275496A (he) מעכבי גליקולאט אוקסידאז לטיפול במחלה
IL279260A (he) מעכבי kdm1a לטיפול במחלות
IL264048A (he) מעכבי pde9 לטיפול במחלות היקפיות
GB201804514D0 (en) Treatment of pyroptosis
ZA201703003B (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases
SG11202006374VA (en) Treatment of demyelinating diseases
IL274541A (he) שיטה לטיפול במחלות של דרכי העיכול באמצעות טראדיפיטנט
IL266275A (he) טיפול במחלות cns על ידי מריצי sgc
IL287904A (he) טיפול משולב במחלת דלקת פרקים
IL252187A0 (he) שימוש במעכבי pan fgfr ושיטה לזיהוי חולים עם סרטן המתאימים לטיפול עם מעכב pan fgfr
IL283508A (he) שיטות טיפול במחלות עם מעכבי magl
IL279623A (he) שיטה לזיהוי מטופלים עם סיכוי סביר ליהנות מטיפול במעכב טלומראז
GB201804515D0 (en) Treatment of necroptosis
GB202015959D0 (en) Treatment of diseases involving NAD
IL284791A (he) שיטות טיפול במחלות עם מעכבי magl
GB201805100D0 (en) Treatment of sarcopenic diseases
HUE064403T2 (hu) A H3-ligandumok új terápiás alkalmazása
IL286099A (he) שיטות לטיפול במחלה תוך שימוש ב-levoketoconazole
IL290983A (he) שיטות לטיפול
GB201918853D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment
GB201909438D0 (en) Treatment of diseases